Calithera Biosciences Offers Clinical Data Presentation at ASCO '15

Calithera Biosciences, Inc.

, a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that clinical data for its lead drug candidate CB-839, the Company's novel, orally bioavailable glutaminase inhibitor, will be presented at the 51^st Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 29 to June 2, 2015 in Chicago, Illinois. Clinical results to be presented include updated data from Calithera's Phase I trial in solid tumors. Calithera will hold an investor and analyst briefing Saturday, May 30, 2015 in Chicago, Illinois at 6:30 p.m. CT. Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors Abstract: #2512 Presenter: James J. Harding, MD, Memorial Sloan Kettering Cancer Center Date: May 30, 2015 Poster Display: 8:00 a.m. - 11:30 a.m. CT Developmental Therapeutics and Translational Research, S Hall A, Board 228 Poster Discussion: 1:15 p.m. - 2:30 p.m. CT, Room S406